Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.

Pigment cell & melanoma research - 1 Mar 2017

Mesbah Ardakani Nima, Leslie Connull, Grieu-Iacopetta Fabienne, Lam Wei-Sen, Budgeon Charley, Millward Michael, Amanuel Benhur

Abstract excerpt

Heterogeneity of BRAF mutation in melanoma has been a controversial subject. Quantitative data on BRAF allele frequency (AF) are sparse, and the potential relationship with response to BRAF inhibitors (BRAFi) in patients with metastatic melanoma is unknown. We quantitatively measured BRAF AF in a cohort of treatment naïve metastatic melanoma samples by pyrosequencing and correlated with survival data in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Gene Frequency

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Melanoma

Share to Prognosis

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Identifiers

PMID: 28002643
DOI: 10.1111/pcmr.12569

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma.PMID 28002643Read ↗

High BRAF variant allele frequencies are associated with distinct pathological features and responsiveness to target therapy in melanoma patients.Semantic proximity Read ↗

Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutationsSemantic proximity Read ↗

Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.Semantic proximity Read ↗

Dissecting the Spectrum of Rare BRAF Mutations in Melanoma: A Nation-Wide Study by the Italian Melanoma Intergroup (IMI).Semantic proximity Read ↗

BRAF Mutation Heterogeneity in Melanoma Lesions.Semantic proximity Read ↗

Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.Semantic proximity Read ↗

BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors.Semantic proximity Read ↗

BRAF mutation screening in melanoma: is sentinel lymph node reliable?Semantic proximity Read ↗

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice.Semantic proximity Read ↗

Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.Semantic proximity Read ↗

Variations of BRAF mutant allele percentage in melanomas.Semantic proximity Read ↗

Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.